Compugen Q3 2026: Revenue Nearly 3x Estimates With Binary Catalyst Ahead

Compugen reported Q3 2026 revenue of $3.82 million, coming in 291.9% above the consensus estimate of $975,000, as the company recognized portions of both the Gilead upfront payment and an IND milestone under its IL-18 binding protein antibody licensing agreement. That deal has generated $90 million in gross payments to date and carries up to $758 million in additional potential milestones, putting the revenue line in a very different light than the headline number alone would suggest.

On the bottom line, the company posted GAAP EPS of negative $0.06, exceeding expectations for negative $0.09. The net loss narrowed to approximately $5.8 million, or $0.06 per share, from approximately $7.0 million, or $0.07 per share, in the same quarter a year earlier. R&D expenses held flat year over year at approximately $5.8 million, keeping the operating cost base stable while partnership revenue did the heavy lifting.

The company holds $117.5 million in cash, deposits, and marketable securities, which management says funds operations into 2029. That runway, extended by the Gilead milestone recognition, removes near-term financing pressure and allows the company to reach its most important clinical readout without dilutive fundraising hanging over the stock.

That readout is MAIA-ovarian, a trial of COM701 in relapsed platinum-sensitive ovarian cancer that is now fully enrolled with 62 patients. CEO Eran Ophir confirmed the company remains on track to report results by the end of Q1 2027. With a market cap of roughly $186 million, those results represent a binary event for the value of the asset in a setting where there is currently no approved maintenance treatment option.

Beyond the COM701 catalyst, partner AstraZeneca is running rilvegostomig, a PD-1/TIGIT bispecific, across 12 ongoing Phase 3 trials. High-level results from the ARTEMIDE-Biliary01 study in adjuvant biliary tract cancer are expected in the second half of 2027. Compugen could receive up to $195 million in additional AstraZeneca milestones plus tiered royalties, so the AstraZeneca pipeline represents a meaningful secondary value driver running in parallel to the COM701 readout.

Compugen also introduced UnigenX, an expansion of its AI-driven discovery platform aimed at identifying novel tumor-associated antigens for modalities such as T cell engagers. Management framed 2027 as a data-rich year, with the MAIA-ovarian readout, the AstraZeneca Phase 3 data, and early pipeline progress all expected to converge within roughly 12 months of this report.